Quote | Faron Pharmaceuticals Oy (OTCMKTS:FPHAF)
Last: | $3.30 |
---|---|
Change Percent: | 0.0% |
Open: | $3.3 |
Close: | $3.30 |
High: | $3.3 |
Low: | $3.3 |
Volume: | 1,654 |
Last Trade Date Time: | 02/11/2022 04:53:46 pm |
News | Faron Pharmaceuticals Oy (OTCMKTS:FPHAF)
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients. 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up. While data do not yet all...
(NewsDirect) Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndr...
Message Board Posts | Faron Pharmaceuticals Oy (OTCMKTS:FPHAF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Faron Pharmaceuticals Oy Company Name:
FPHAF Stock Symbol:
OTCMKTS Market:
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients. 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up. While data do not yet all...
(NewsDirect) Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndr...
TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvi...